Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Dostarlimab in Indian Patients with Advanced Endometrial Cancer
NCT06897527Phase 4Not yet recruiting
- Sponsor
- GSK
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 4, open-label, single-arm trial of dostarlimab in endometrial cancer (EC), sponsored by GSK. Primary endpoint: Number of Participants with Grade 3 or greater Treatment Emergent Adverse Events up to 25 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06897527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897527.